BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29670214)

  • 21. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
    Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
    Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric.
    Kaufmann D; Hoesch J; Su Y; Deeg L; Mellert K; Spatz JP; Kemkemer R
    Mol Syndromol; 2012 Oct; 3(4):169-79. PubMed ID: 23239959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
    Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
    Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
    Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
    J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
    Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
    Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibromin (Nf1) is required for skeletal muscle development.
    Kossler N; Stricker S; Rödelsperger C; Robinson PN; Kim J; Dietrich C; Osswald M; Kühnisch J; Stevenson DA; Braun T; Mundlos S; Kolanczyk M
    Hum Mol Genet; 2011 Jul; 20(14):2697-709. PubMed ID: 21478499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
    Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
    Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP-dependent protein kinase.
    Izawa I; Tamaki N; Saya H
    FEBS Lett; 1996 Mar; 382(1-2):53-9. PubMed ID: 8612763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the French Canadian variant of Leigh's syndrome in a common molecular complex.
    Arun V; Wiley JC; Kaur H; Kaplan DR; Guha A
    J Neurosci Res; 2013 Apr; 91(4):494-505. PubMed ID: 23361976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.
    Bai RY; Esposito D; Tam AJ; McCormick F; Riggins GJ; Wade Clapp D; Staedtke V
    Gene Ther; 2019 Jun; 26(6):277-286. PubMed ID: 31127187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
    Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
    Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
    Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
    Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.
    Yunoue S; Tokuo H; Fukunaga K; Feng L; Ozawa T; Nishi T; Kikuchi A; Hattori S; Kuratsu J; Saya H; Araki N
    J Biol Chem; 2003 Jul; 278(29):26958-69. PubMed ID: 12730209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
    Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
    Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
    Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
    Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
    Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
    Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated proteomics identified novel activation of dynein IC2-GR-COX-1 signaling in neurofibromatosis type I (NF1) disease model cells.
    Hirayama M; Kobayashi D; Mizuguchi S; Morikawa T; Nagayama M; Midorikawa U; Wilson MM; Nambu AN; Yoshizawa AC; Kawano S; Araki N
    Mol Cell Proteomics; 2013 May; 12(5):1377-94. PubMed ID: 23358504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.